D&D Pharmatech FY 2025 Annual Report
Beta

Filed: March 20, 2026· period ending December 31, 2025DART

D&D Pharmatech annual report for FY 2025, filed with DART (Korea Financial Supervisory Service) on March 20, 2026. This page provides AI-powered English analysis including business overview, management discussion & analysis (MD&A), risk factors, and KIFRS consolidated financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE).

D&D Pharmatech FY 2025 Annual Report Analysis

Business Overview

• Core business: peptide-based innovative drug R&D with GLP-1 obesity oral drugs and MASH treatment DD01, plus neurodegenerative and fibrosis therapy pipelines
• DD01 MASH drug clinical 2nd phase in US reached primary endpoint June 2025; China partner Salubris got obesity IND approval Dec 2024

Management Discussion & Analysis

• Revenue KRW 4.298B (-62.42% YoY), operating loss KRW 33.993B (-35.88%), net loss KRW 23.980B (-18.67%)
• MASH therapy DD01 segment drove R&D focus; continued US Phase 2 clinical trial with clinical progress and data acquisition

Risk Factors

• USD 766M net foreign currency exposure at FY2025-end, down from USD 3.57B at FY2024-end
• USD 10% exchange rate move impacts pre-tax net income by ±KRW 76.6M in FY2025, down from ±KRW 357M in FY2024

D&D Pharmatech FY 2025 Key Financial Metrics
DART

Total Assets

KRW 97.5B

▲ +0.0% YoY

Operating Cash Flow

-KRW 21.1B

▲ +3.1% YoY

CapEx

-KRW 64.4M

▲ +83.7% YoY

Source: KIFRS consolidated financial data from D&D Pharmatech annual report on DART. All figures in KRW.

Source: DART (Korea Financial Supervisory Service) · AI summaries generated from the original Korean filing (English output) · Beta: coverage is expanding